

Feng Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8834590/publications.pdf>

Version: 2024-02-01

142
papers

3,595
citations

159585

30
h-index

168389

53
g-index

149
all docs

149
docs citations

149
times ranked

5361
citing authors

#	ARTICLE	IF	CITATIONS
1	What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. <i>Value in Health</i> , 2022, 25, 302-317.	0.3	11
2	More work needed on decision analysis for shared decision-making: A scoping review. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 106-120.	5.0	4
3	Transforming challenges into opportunities: conducting health preference research during the COVID-19 pandemic and beyond. <i>Quality of Life Research</i> , 2022, 31, 1191-1198.	3.1	1
4	Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 133-143.	5.0	2
5	Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 254-261.e1.	0.8	10
6	A Systematic Literature Review of Health Utility Values in Breast Cancer. <i>Medical Decision Making</i> , 2022, 42, 704-719.	2.4	4
7	RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. <i>PLoS ONE</i> , 2022, 17, e0261767.	2.5	9
8	Population Norms for SF-6Dv2 and EQ-5D-5L in China. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 573-585.	2.1	15
9	Be Healthy in Pregnancy (BHIP): A Randomized Controlled Trial of Nutrition and Exercise Intervention from Early Pregnancy to Achieve Recommended Gestational Weight Gain. <i>Nutrients</i> , 2022, 14, 810.	4.1	19
10	Methodologic and Reporting Quality of Economic Evaluations in Hand and Wrist Surgery: A Systematic Review. <i>Plastic and Reconstructive Surgery</i> , 2022, 149, 453e-464e.	1.4	0
11	How Do Health Schemas Inform Healthy Behaviours During Pregnancy? Qualitative Findings from the Be Healthy in Pregnancy (BHIP) Study. <i>Maternal and Child Health Journal</i> , 2022, , 1.	1.5	0
12	Fighting COVID-19: a qualitative study into the lives of intensive care unit survivors in Wuhan, China. <i>BMJ Open</i> , 2022, 12, e055365.	1.9	2
13	Time-Specific Differences in Stated Preferences for Health in the United States. <i>Medical Care</i> , 2022, Publish Ahead of Print, .	2.4	0
14	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). <i>Clinical Genitourinary Cancer</i> , 2022, 20, e353-e361.	1.9	3
15	A look back at the first wave of COVID-19 in China: A systematic review and meta-analysis of mortality and health care resource use among severe or critical patients. <i>PLoS ONE</i> , 2022, 17, e0265117.	2.5	7
16	Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). <i>BMJ Open</i> , 2022, 12, e053246.	1.9	11
17	Responsiveness of the HUG-5 in an outpatient clinic: a 12-month randomised feasibility study protocol. <i>BMJ Open</i> , 2022, 12, e061057.	1.9	0
18	Indirectness (transferability) is critical when considering existing economic evaluations for GRADE clinical practice guidelines: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 81-92.	5.0	1

#	ARTICLE	IF	CITATIONS
19	China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population. <i>Pharmacoeconomics</i> , 2022, 40, 957-969.	3.3	1
20	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 208.	1.1	9
21	Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. <i>BMJ Open</i> , 2021, 11, e046021.	1.9	4
22	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	2.8	7
23	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021, 39, 1075-1084.	3.3	0
24	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1488-1498.	7.1	22
25	Patient-Reported Outcomes and Patient-Reported Experience of Patients With Atrial Fibrillation in the IMPACT-AF Clinical Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e019783.	3.7	4
26	Guidelines that use the GRADE approach often fail to provide complete economic information for recommendations: A systematic survey. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 203-215.	5.0	6
27	Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. <i>JAMA Network Open</i> , 2021, 4, e2122079.	5.9	3
28	GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 138-150.	5.0	81
29	Quantifying the impacts of human mobility restriction on the spread of coronavirus disease 2019: an empirical analysis from 344 cities of China. <i>Chinese Medical Journal</i> , 2021, 134, 2438-2446.	2.3	0
30	Temporal Trends and Factors Associated With the Inclusion of Patient-Reported Outcomes in Heart Failure Randomized Controlled Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2021, 10, e022353.	3.7	10
31	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. <i>Blood Advances</i> , 2021, , .	5.2	7
32	Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada. <i>JAMA Surgery</i> , 2020, 155, e201985.	4.3	13
33	3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set. <i>Quality of Life Research</i> , 2020, 29, 3109-3118.	3.1	0
34	A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for Living Fetuses (ILIFE) trial. <i>Trials</i> , 2020, 21, 771.	1.6	12
35	International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. <i>BMJ Open</i> , 2020, 10, e034451.	1.9	4
36	Acceptability and Validity of the EQ-5D in Patients Living With Dementia. <i>Value in Health</i> , 2020, 23, 760-767.	0.3	17

#	ARTICLE	IF	CITATIONS
37	Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. <i>Medical Decision Making</i> , 2020, 40, 483-497.	2.4	2
38	Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials. <i>European Journal of Health Economics</i> , 2020, 21, 717-728.	2.8	12
39	Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. <i>American Heart Journal</i> , 2020, 224, 35-46.	2.7	27
40	An Exploratory Analysis of Predictors of Concordance Between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta. <i>Healthcare Policy</i> , 2020, 15, 90-101.	0.6	2
41	United States Valuation of EQ-5D-5L Health States Using an International Protocol. <i>Value in Health</i> , 2019, 22, 931-941.	0.3	204
42	Cost-effectiveness of a collaborative dementia care management—Results of a cluster-randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 1296-1308.	0.8	49
43	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. <i>Medical Decision Making</i> , 2019, 39, 605-616.	2.4	42
44	Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. <i>Clinical Therapeutics</i> , 2019, 41, 2308-2320.e11.	2.5	25
45	Experiences regarding nutrition and exercise among women during early postpartum: a qualitative grounded theory study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 368.	2.4	32
46	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019, 39, 371-379.	2.4	14
47	Canada's Amendment to Patented Drug Price Regulation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1565.	7.4	5
48	Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. <i>Medical Decision Making</i> , 2019, 39, 421-436.	2.4	5
49	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 753.	7.4	176
50	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. <i>Cancer Treatment Reviews</i> , 2019, 74, 43-48.	7.7	38
51	Disease-specific Preference-based Measure of Glaucoma Health States: HUG-5 Psychometric Validation. <i>Journal of Glaucoma</i> , 2019, 28, 593-600.	1.6	5
52	GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inconsistency, imprecision, and other domains. <i>Journal of Clinical Epidemiology</i> , 2019, 111, 83-93.	5.0	146
53	Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 349-357.	3.7	41
54	Robotic Versus Video-Assisted Thoracoscopic Lung Resection During Early Program Development. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1050-1057.	1.3	22

#	ARTICLE	IF	CITATIONS
55	Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. <i>American Heart Journal</i> , 2018, 199, 75-82.	2.7	24
56	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). <i>Health and Quality of Life Outcomes</i> , 2018, 16, 78.	2.4	20
57	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. <i>American Heart Journal</i> , 2018, 201, 149-157.	2.7	23
58	Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada. <i>Pharmacoeconomics - Open</i> , 2018, 2, 19-29.	1.8	8
59	Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. <i>Medical Decision Making</i> , 2018, 38, 26-33.	2.4	4
60	P465: COST-UTILITY ANALYSIS OF DEMENTIA CARE MANAGEMENT: RESULTS OF THE CLUSTER-RANDOMIZED, CONTROLLED, INTERVENTIONAL TRIAL DELPHI-MV. <i>Alzheimer's and Dementia</i> , 2018, 14, P1502.	0.8	0
61	Structured diet and exercise guidance in pregnancy to improve health in women and their offspring: study protocol for the Be Healthy in Pregnancy (BHIP) randomized controlled trial. <i>Trials</i> , 2018, 19, 691.	1.6	17
62	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3053.	4.0	4
63	FIT for FUNCTION: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 39.	1.6	11
64	Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. <i>Pharmacoeconomics</i> , 2018, 36, 883-888.	3.3	4
65	Preference-based Glaucoma-specific Health-related Quality of Life Instrument: Development of the Health Utility for Glaucoma. <i>Journal of Glaucoma</i> , 2018, 27, 585-591.	1.6	5
66	A Computer-Assisted Personal Interview App in Research Electronic Data Capture for Administering Time Trade-off Surveys (REDCap): Development and Pretest. <i>JMIR Formative Research</i> , 2018, 2, e3.	1.4	5
67	Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments. <i>Medical Decision Making</i> , 2017, 37, 262-272.	2.4	10
68	Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. <i>Value in Health</i> , 2017, 20, 644-650.	0.3	170
69	Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. <i>Clinical Chemistry</i> , 2017, 63, 593-602.	3.2	11
70	Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2017, 26, 1483-1492.	3.1	5
71	Feasibility of an altruistic sperm donation program in Canada: results from a population-based model. <i>Reproductive Health</i> , 2017, 14, 8.	3.1	4
72	Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies. <i>Journal of Clinical Epidemiology</i> , 2017, 85, 21-31.	5.0	18

#	ARTICLE	IF	CITATIONS
73	Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. <i>Quality of Life Research</i> , 2017, 26, 2057-2066.	3.1	33
74	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017, 18, 967-977.	2.8	8
75	Transforming Latent Utilities to Health Utilities: East Does Not Meet West. <i>Health Economics (United Kingdom)</i> 10.1007/s11175-017-0185-1	1.7	18
76	Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. <i>JAMA Oncology</i> , 2017, 3, 366.	7.1	68
77	The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. <i>Obesity Surgery</i> , 2017, 27, 349-356.	2.1	30
78	Pulmonary Rehabilitation With Balance Training for Fall Reduction in Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2017, 6, e228.	1.0	7
79	A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. <i>Medical Care</i> , 2016, 54, 98-105.	2.4	290
80	Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol. <i>BMJ Open</i> , 2016, 6, e012732.	1.9	8
81	Is bad living better than good death? Impact of demographic and cultural factors on health state preference. <i>Quality of Life Research</i> , 2016, 25, 979-986.	3.1	21
82	Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2016, 25, 1679-1685.	3.1	27
83	How different are composite and traditional TTO valuations of severe EQ-5D-5L states?. <i>Quality of Life Research</i> , 2016, 25, 2101-2108.	3.1	7
84	Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e012909.	1.9	11
85	Behavioral activation group therapy for reducing depressive symptoms and improving quality of life: a feasibility study. <i>Pilot and Feasibility Studies</i> , 2016, 2, 22.	1.2	10
86	Can the general public use vignettes to discriminate between Alzheimer's disease health states?. <i>BMC Geriatrics</i> , 2016, 16, 36.	2.7	7
87	EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada. <i>Quality of Life Research</i> , 2016, 25, 3009-3016.	3.1	25
88	Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. <i>Pharmacoeconomics</i> , 2016, 34, 1087-1100.	3.3	154
89	Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility. <i>Medical Decision Making</i> , 2016, 36, 223-233.	2.4	11
90	How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations. <i>Quality of Life Research</i> , 2016, 25, 35-43.	3.1	12

#	ARTICLE	IF	CITATIONS
91	Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study. PLoS ONE, 2016, 11, e0162422.	2.5	5
92	A pragmatic pilot randomized trial to investigate the effectiveness of behavioural activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: the BRAVE pilot trial protocol. Pilot and Feasibility Studies, 2015, 1, 39.	1.2	6
93	Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?. European Journal of Health Economics, 2015, 16, 847-855.	2.8	15
94	Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2015, 33, 2296-2302.	1.6	43
95	The economics of adalimumab for ulcerative colitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 373-377.	1.4	2
96	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics, 2015, 33, 867-877.	3.3	45
97	Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study. Hospital Practice (1995), 2014, 42, 38-45.	1.0	5
98	Comparing EQ-5D Valuation Studies. Medical Decision Making, 2014, 34, 8-20.	2.4	84
99	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 2014, 52, 935-943.	2.4	38
100	Assessment of Preference for Hormonal Treatment-Related Health States among Patients with Breast Cancer. Value in Health Regional Issues, 2014, 3, 27-32.	1.2	8
101	Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling?. European Journal of Health Economics, 2014, 15, 281-288.	2.8	30
102	Cost-Effectiveness of Pharmaceutical Management for Osteoarthritis Pain. Drugs and Aging, 2013, 30, 277-284.	2.7	9
103	Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. Pharmacoeconomics, 2013, 31, 501-508.	3.3	24
104	Cost Effectiveness of Treatment Options for Early Prostate Cancer: Can We Put the Puzzle Pieces Together?. European Urology, 2013, 63, 411-412.	1.9	0
105	Scoring the 5-Level EQ-5D. Medical Decision Making, 2013, 33, 567-578.	2.4	7
106	Model-based economic evaluation for medical decision making: learn from the past and prepare for the future. Journal of Thoracic Disease, 2013, 5, 209-10.	1.4	3
107	Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study. Hospital Practice (1995), 2012, 40, 131-137.	1.0	5
108	Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2012, 35, 259-275.	1.3	13

#	ARTICLE	IF	CITATIONS
109	Health State Utility Assessment for Breast Cancer. <i>Value in Health Regional Issues</i> , 2012, 1, 93-97.	1.2	19
110	Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. <i>Value in Health Regional Issues</i> , 2012, 1, 46-53.	1.2	9
111	The excess burden of osteoarthritis in the province of Ontario, Canada. <i>Arthritis and Rheumatism</i> , 2012, 64, 1153-1161.	6.7	39
112	Measuring health-related quality-of-life for Alzheimer's disease using the general public. <i>Quality of Life Research</i> , 2012, 21, 593-601.	3.1	9
113	Triple Therapy for the Management of COPD: A Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 206-243.	1.6	21
114	Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 513-521.	1.4	10
115	Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis. <i>International Journal of Rheumatic Diseases</i> , 2011, 14, 206-210.	1.9	34
116	Health economic evaluations help inform payers of the best use of scarce health care resources. <i>International Journal of Circumpolar Health</i> , 2011, 70, 419-427.	1.2	10
117	Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 89.	1.9	84
118	Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. <i>Medical Decision Making</i> , 2011, 31, 790-799.	2.4	13
119	Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. <i>European Journal of Health Economics</i> , 2010, 11, 27-34.	2.8	24
120	Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 87.	2.4	32
121	Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. <i>Value in Health</i> , 2010, 13, 487-494.	0.3	120
122	Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. <i>Value in Health</i> , 2010, 13, S8-S11.	0.3	7
123	Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index. <i>Value in Health</i> , 2010, 13, 873-878.	0.3	45
124	Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. <i>Clinical Therapeutics</i> , 2009, 31, 1082-1091.	2.5	15
125	Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 20.	1.5	35
126	A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. <i>Value in Health</i> , 2009, 12, 245-252.	0.3	37

#	ARTICLE	IF	CITATIONS
127	Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. Journal of the American College of Radiology, 2009, 6, 317-323.	1.8	25
128	Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology, 2009, 6, 324-331.	1.8	7
129	Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology, 2009, 6, 332-342.	1.8	18
130	Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement. Quality of Life Research, 2008, 17, 595-601.	3.1	95
131	The need for standardization: A literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis and Rheumatism, 2008, 59, 1027-1033.	6.7	25
132	Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies: A Study in a Multiethnic Asian Population in Singapore. Value in Health, 2008, 11, S3-S10.	0.3	24
133	A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore. Value in Health, 2008, 11, S84-S90.	0.3	39
134	Validation of the International Classification of Functioning, Disability, and Health (ICF) Brief Core Set for osteoarthritis. Scandinavian Journal of Rheumatology, 2008, 37, 450-461.	1.1	16
135	Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. International Journal of Technology Assessment in Health Care, 2008, 24, 87-95.	0.5	25
136	Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer: A markov model. World Journal of Gastroenterology, 2008, 14, 3021.	3.3	34
137	Comparison of the EuroQol and short form 6D in Singapore multiethnic asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis and Rheumatism, 2007, 57, 1043-1049.	6.7	43
138	True Difference or Something Else? Problems in Cost of Osteoarthritis Studies. Seminars in Arthritis and Rheumatism, 2007, 37, 127-132.	3.4	26
139	Direct and indirect costs of osteoarthritis in Singapore: a comparative study among multiethnic Asian patients with osteoarthritis. Journal of Rheumatology, 2007, 34, 165-71.	2.0	28
140	Validation of the Comprehensive ICF Core Set for Osteoarthritis (OA) in patients with knee OA: a Singaporean perspective. Journal of Rheumatology, 2007, 34, 2301-7.	2.0	9
141	Do Health-Related Quality-of-Life Domains and Items in Knee and Hip Osteoarthritis Vary in Importance Across Social-Cultural Contexts? A Qualitative Systematic Literature Review. Seminars in Arthritis and Rheumatism, 2005, 34, 793-804.	3.4	24
142	Industry sponsorship bias in cost effectiveness analysis: registry based analysis. BMJ, The, 0, , e069573.	6.0	13